Government-Owned Inventions; Availability for Licensing, 38922-38923 [2014-16029]
Download as PDF
<![CDATA[
38922
Federal Register / Vol. 79, No. 131 / Wednesday, July 9, 2014 / Notices
ESTIMATES OF ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Type of respondents
Applicant Survey ..............................................................................................
Dated: July 2, 2014.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2014–16072 Filed 7–8–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive Evaluation Option License
Agreement: AAV Mediated
Aquaporin-1 Gene Transfer To Treat
¨
Sjogren’s Syndrome
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health
(NIH), Department of Health and Human
Services (HHS), is contemplating the
grant of a Start-Up Exclusive Evaluation
Option License Agreement to Milo, LLC,
a company having its headquarters in
Cleveland, Ohio, to practice the
inventions embodied in U.S. Provisional
Patent Application No. 61/695,753, filed
20 April 2011 (HHS Ref. No. E–139–
2011/1–US–01]), and PCT Patent
Application No. PCT/US13/57632, filed
30 August 2013 (HHS Ref. No. E–139–
2011/1–PCT–02), entitled ‘‘AAV
Mediated Aquaporin-1 Gene Transfer to
¨
Treat Sjogren’s Syndrome.’’ The patent
rights in these inventions have been
assigned to or exclusively licensed to
the Government of the United States of
America. The territory of the
prospective license may be worldwide
and the field of use may be limited to:
‘‘the use of the Licensed Patent Rights,
limited to AAV mediated aquaporin-1,
¨
for the treatment of Sjogren’s syndrome
in humans.’’
Upon the expiration or termination of
the Start-Up Exclusive Evaluation
Option License Agreement, Milo will
have the exclusive right to execute a
Start-up Exclusive Patent License
Agreement which will supersede and
replace the Start-up Exclusive
Evaluation Option License Agreement,
with no greater field of use and territory
sroberts on DSK5SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
20:08 Jul 08, 2014
Jkt 232001
240
than granted in the Start-Up Exclusive
Evaluation Option License Agreement.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before July
24, 2014 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments
and other materials relating to the
contemplated Start-Up Exclusive
Evaluation Option License Agreement
should be directed to: Vince Contreras,
Ph.D., Licensing and Patenting Manager,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
4711; Facsimile: (301) 402–0220; Email:
vince.contreras@nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published or issued by the United States
Patent and Trademark Office or the
World Intellectual Property
Organization.
The
subject technology includes methods of
¨
treating Sjogren’s syndrome by using
recombinant adeno associated virus
(rAAV) serotypes as vectors to deliver a
gene that expresses AQP1. Aquaporin-1
is a pore protein that selectively
channels water molecules across the cell
membrane. Using animal models that
mimic the dry mouth symptoms
¨
(xerostomia) of Sjogren’s, it was
discovered that there was restoration of
fluid movement upon expression of
AQP1. This potentially represents a
long-term treatment for restoring
¨
exocrine gland function in Sjogren’s
patients where salivary gland activity is
significantly reduced.
The prospective Start-Up Exclusive
Evaluation Option License Agreement
will be royalty bearing and will comply
with the terms and conditions of 35
U.S.C. 209 and 37 CFR part 404. The
prospective Start-Up Exclusive
Evaluation Option License Agreement
and a subsequent Start-Up Exclusive
Patent License Agreement may be
granted unless the NIH receives, within
fifteen (15) days from the date of this
published notice, written evidence and
argument that establishes that the grant
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden per
response
(in hours)
1
Total annual
burden hours
20/60
80
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this Notice will be treated
as objections to the grant of the
contemplated Start-Up Exclusive
Evaluation Option License Agreement.
Comments and objections submitted in
response to this Notice will not be made
available for public inspection, and, to
the extent permitted by law, will not be
released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: July 7, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–16030 Filed 7–8–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR Part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
SUMMARY:
E:\FR\FM\09JYN1.SGM
09JYN1
Federal Register / Vol. 79, No. 131 / Wednesday, July 9, 2014 / Notices
sroberts on DSK5SPTVN1PROD with NOTICES
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
Interactive Clinical Protocol Services
Software
Description of Technology: The
invention pertains to a C/C++ and C
sharp application toolkit named
(Interactive Protocol Services) iPS that
loads into the Allscripts HealthCare
System as a Dynamic Link Library
(DLL). The application provides users
with a GUI that opens into a window of
one of the SCM’s tabs. The toolkit could
be rendered compatible with any offthe-shelf healthcare system that allows
loading library files. The toolkit
provides healthcare professionals with a
custom structure language to be used in
designing customized layouts and
accessing data sources within the
patient care. This custom structure
language is provided to iPS during the
COTS (e.g., SCM) application startup
process or during an interface
communication transaction. Usually,
the custom structured language or
design layout is stored in the COTS
application database system and is
retrieved during the startup process of
iPS. The custom structure language
instructs iPS in how to build and
manipulate defined User Control
Widgets through properties. These
defined User Control Widgets are
created in object pairs. These object
pairs can be accessible through the iPS
application/DLL. iPS also contains a
nested list of layout controls that place
the User Control Widgets at certain
coordinates on the display screen. Each
User Control Widget contains code
events that allow it to respond to userdefined events, actions, web commands
and SQL procedure calls.
Potential Commercial Applications:
• COTS healthcare system.
• Medical/hospital information
systems.
Competitive Advantages:
• Customized views.
• Integrates into exiting management
tool libraries.
Development Stage:
• Early-stage.
• Prototype.
Inventor: Steven D. Moore (NIH–CC).
Intellectual Property: HHS Reference
No. E–172–2014/0—Software. Patent
protection is not being pursued for this
technology.
Licensing Contact: Michael
Shmilovich, Esq., CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The NIH Clinical Center is seeking
statements of capability or interest from
VerDate Mar<15>2010
20:08 Jul 08, 2014
Jkt 232001
parties interested in collaborative
research to further develop, evaluate or
commercialize Interactive Clinical
Protocol Services Software. For
collaboration opportunities, please
contact Eric Cole at colee@cc.nih.gov or
301–451–4430.
Non-Contact Total Emission Detection
Methods for Multiphoton Microscopy:
Improved Image Fidelity and Biological
Sample Analysis
Description of Technology: The
technology offered for licensing and for
further development is in the field of
multiphoton microscopy (MPM). More
specifically, the invention pertains to
optical designs that can enhance and
extend the capabilities of MPM in
spectral imaging of biological samples.
The unique design of the light collection
and the detection optics maximizes the
collection of emitted light, thus
increasing the signal and hence the
signal-to-noise ratio (SNR).
Improvement in image fidelity will
result in improved analysis of biological
samples and thus will favorably impact
medical research and possibly clinical
diagnosis. The present technology is a
further improvement on the TED (Total
Emission Detection) technology, first
disclosed by Dr. Robert Balaban et al. at
the NIH in 2006 and claimed in US
Patent 7,667,210 (issued February 23,
2010). The earlier NIH TED technology
proposed an optical design based on
enveloping the entirety of a small
sample in a parabolic mirror/condenser
combination so light emanated by a
sample in all directions is redirected to
the detector. The present technology
further expands the capabilities of TED
as its unique design employing
parabolic, toric and conic mirrors
ensures maximum light collection from
large samples in cases where there is
only access to one side of the tissues
(e.g., in vivo or ex vivo). This is
accomplished by the redirection of all
attainable light (i.e., light escaping the
tissue or a whole animal in the epi and
sideway directions) to the detector.
Potential Commercial Applications:
• Tissue and cell analysis in
biomedical research.
• Potential applications in clinical
diagnostics.
Competitive Advantages:
• Increased signal-to-noise ratio.
• Enhanced image resolution due to
SNR.
• Improved analytical capabilities.
• Non-contact.
• May readily be adaptable to
commercial microscopes.
Development Stage:
• In vitro data available.
• Prototype.
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
38923
Inventors: Jay R. Knutson, Christian
A. Combs, Robert S. Balaban (all of
NHLBI).
Publications:
1. Combs CA, et al. Optimization of
multiphoton excitation microscopy by
total emission detection using a
parabolic light reflector. J Microsc. 2007
Dec;228(Pt3):330–7. [PMID 18045327]
2. Combs CA, et al. Compact non-contact
total emission detection for in vivo
multiphoton excitation microscopy. J
Microsc. 2014 Feb;253(2):83–92. [PMID
24251437]
3. Combs CA, et al. Optimizing multiphoton
fluorescence microscopy light collection
from living tissue by noncontact total
emission detection (epiTED). J Microsc.
2011 Feb;241(2):153–61. [PMID
21118209]
Intellectual Property: HHS Reference
No. E–236–2009/0—
• US Provisional Patent Application
61/224,772 filed July 10, 2009.
• US Patent 8,759,792 issued June 24,
2014.
• European Patent Application
10797972.6 filed July 12, 2010.
Related Technology: HHS Reference
No. E–257–2005/0—US Patent
7,667,210 issued February 23, 2010.
Licensing Contact: Michael
Shmilovich, Esq., CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The NHLBI Laboratory of Molecular
Biophysics is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize an enhanced method of
multiphoton microscopy that is suitable
for the spectral imaging of biological
samples. Please contact Brian W. Bailey,
Ph.D. at bbailey@mail.nih.gov for more
information.
Dated: July 7, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–16029 Filed 7–8–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\09JYN1.SGM
09JYN1
]]>Agencies
[Federal Register Volume 79, Number 131 (Wednesday, July 9, 2014)]
[Notices]
[Pages 38922-38923]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-16029]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will
[[Page 38923]]
be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Interactive Clinical Protocol Services Software
Description of Technology: The invention pertains to a C/C++ and C
sharp application toolkit named (Interactive Protocol Services) iPS
that loads into the Allscripts HealthCare System as a Dynamic Link
Library (DLL). The application provides users with a GUI that opens
into a window of one of the SCM's tabs. The toolkit could be rendered
compatible with any off-the-shelf healthcare system that allows loading
library files. The toolkit provides healthcare professionals with a
custom structure language to be used in designing customized layouts
and accessing data sources within the patient care. This custom
structure language is provided to iPS during the COTS (e.g., SCM)
application startup process or during an interface communication
transaction. Usually, the custom structured language or design layout
is stored in the COTS application database system and is retrieved
during the startup process of iPS. The custom structure language
instructs iPS in how to build and manipulate defined User Control
Widgets through properties. These defined User Control Widgets are
created in object pairs. These object pairs can be accessible through
the iPS application/DLL. iPS also contains a nested list of layout
controls that place the User Control Widgets at certain coordinates on
the display screen. Each User Control Widget contains code events that
allow it to respond to user-defined events, actions, web commands and
SQL procedure calls.
Potential Commercial Applications:
COTS healthcare system.
Medical/hospital information systems.
Competitive Advantages:
Customized views.
Integrates into exiting management tool libraries.
Development Stage:
Early-stage.
Prototype.
Inventor: Steven D. Moore (NIH-CC).
Intellectual Property: HHS Reference No. E-172-2014/0--Software.
Patent protection is not being pursued for this technology.
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NIH Clinical Center is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate or commercialize
Interactive Clinical Protocol Services Software. For collaboration
opportunities, please contact Eric Cole at colee@cc.nih.gov or 301-451-
4430.
Non-Contact Total Emission Detection Methods for Multiphoton
Microscopy: Improved Image Fidelity and Biological Sample Analysis
Description of Technology: The technology offered for licensing and
for further development is in the field of multiphoton microscopy
(MPM). More specifically, the invention pertains to optical designs
that can enhance and extend the capabilities of MPM in spectral imaging
of biological samples. The unique design of the light collection and
the detection optics maximizes the collection of emitted light, thus
increasing the signal and hence the signal-to-noise ratio (SNR).
Improvement in image fidelity will result in improved analysis of
biological samples and thus will favorably impact medical research and
possibly clinical diagnosis. The present technology is a further
improvement on the TED (Total Emission Detection) technology, first
disclosed by Dr. Robert Balaban et al. at the NIH in 2006 and claimed
in US Patent 7,667,210 (issued February 23, 2010). The earlier NIH TED
technology proposed an optical design based on enveloping the entirety
of a small sample in a parabolic mirror/condenser combination so light
emanated by a sample in all directions is redirected to the detector.
The present technology further expands the capabilities of TED as its
unique design employing parabolic, toric and conic mirrors ensures
maximum light collection from large samples in cases where there is
only access to one side of the tissues (e.g., in vivo or ex vivo). This
is accomplished by the redirection of all attainable light (i.e., light
escaping the tissue or a whole animal in the epi and sideway
directions) to the detector.
Potential Commercial Applications:
Tissue and cell analysis in biomedical research.
Potential applications in clinical diagnostics.
Competitive Advantages:
Increased signal-to-noise ratio.
Enhanced image resolution due to SNR.
Improved analytical capabilities.
Non-contact.
May readily be adaptable to commercial microscopes.
Development Stage:
In vitro data available.
Prototype.
Inventors: Jay R. Knutson, Christian A. Combs, Robert S. Balaban
(all of NHLBI).
Publications:
1. Combs CA, et al. Optimization of multiphoton excitation
microscopy by total emission detection using a parabolic light
reflector. J Microsc. 2007 Dec;228(Pt3):330-7. [PMID 18045327]
2. Combs CA, et al. Compact non-contact total emission detection for
in vivo multiphoton excitation microscopy. J Microsc. 2014
Feb;253(2):83-92. [PMID 24251437]
3. Combs CA, et al. Optimizing multiphoton fluorescence microscopy
light collection from living tissue by noncontact total emission
detection (epiTED). J Microsc. 2011 Feb;241(2):153-61. [PMID
21118209]
Intellectual Property: HHS Reference No. E-236-2009/0--
US Provisional Patent Application 61/224,772 filed July
10, 2009.
US Patent 8,759,792 issued June 24, 2014.
European Patent Application 10797972.6 filed July 12,
2010.
Related Technology: HHS Reference No. E-257-2005/0--US Patent
7,667,210 issued February 23, 2010.
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NHLBI Laboratory of
Molecular Biophysics is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize an enhanced method of multiphoton microscopy
that is suitable for the spectral imaging of biological samples. Please
contact Brian W. Bailey, Ph.D. at bbailey@mail.nih.gov for more
information.
Dated: July 7, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-16029 Filed 7-8-14; 8:45 am]
BILLING CODE 4140-01-P
